Revolution Medicines (NASDAQ:RVMD) vs. Creative Medical Technology (OTCMKTS:CELZ) Financial Analysis

Revolution Medicines (NASDAQ:RVMD – Get Rating) and Creative Medical Technology (OTCMKTS:CELZ – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Earnings & Valuation

This table compares Revolution Medicines and Creative Medical Technology’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$29.39 million	51.24	-$187.09 million	($2.56)	-7.93
Creative Medical Technology	N/A	N/A	N/A	N/A	N/A

Creative Medical Technology has lower revenue, but higher earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	-636.58%	-28.26%	-24.47%
Creative Medical Technology	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Revolution Medicines and Creative Medical Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	0	1	4	0	2.80
Creative Medical Technology	0	0	1	0	3.00

Revolution Medicines presently has a consensus target price of $33.00, indicating a potential upside of 62.56%. Creative Medical Technology has a consensus target price of $10.00, indicating a potential upside of 506.06%. Given Creative Medical Technology’s stronger consensus rating and higher possible upside, analysts plainly believe Creative Medical Technology is more favorable than Revolution Medicines.

Insider & Institutional Ownership

13.7% of Creative Medical Technology shares are owned by institutional investors. 22.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Creative Medical Technology beats Revolution Medicines on 6 of the 9 factors compared between the two stocks.

About Revolution Medicines (Get Rating)

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

About Creative Medical Technology (Get Rating)

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.